Lung Cancer | Specialty

Durvalumab After CRT in Locally Advanced NSCLC

January 14th 2019

Chemotherapy Considerations in Locally Advanced NSCLC

January 14th 2019

CRT in Locally Advanced NSCLC

January 14th 2019

Dr. Davis Discusses Benefits of Robotic Thoracic Surgery

January 11th 2019

J. Russell Davis, MD, clinical professor, University of Missouri-Kansas City School of Medicine, thoracic surgeon, Saint Luke's Hospital, discusses the benefits of robotics in thoracic surgery.

Dr. Wong on the Current Landscape of NSCLC

January 11th 2019

Kwok-Kin Wong, MD, PhD, Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine, and director of the Division of Hematology and Medical Oncology at NYU Langone’s Perlmutter Cancer Center, discusses the current landscape of non–small cell lung cancer (NSCLC).

Treatment Breakthroughs Advance Care Across Heterogeneous NSCLC Population

January 8th 2019

Kwok-Kin Wong, MD, PhD, discusses updates in non–small cell lung cancer and the importance of enrolling patients in clinical trials to further progress the field.

Dr. Sabari Discusses Immunotherapy Biomarkers in NSCLC

January 8th 2019

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, discusses biomarkers of immunotherapy response in non–small cell lung cancer.

Shum Sheds Light on Oncogene-Driven NSCLC Treatment Options

January 7th 2019

Elaine Shum, MD, discusses the rapidly evolving treatment options for patients with oncogene-driven non–small cell lung cancer.

Closer Study Required of Immunological Differences Between Sexes

January 7th 2019

Study results demonstrate that men and women differ in their immunological responses to foreign and self-antigens.

Dr. Perez-Soler on Immunotherapy Advances in SCLC

January 7th 2019

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses recent advances in immunotherapy for the treatment of patients with small cell lung cancer.

Dr. Drilon on Emerging Biomarkers in NSCLC

January 5th 2019

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses emerging biomarkers in non–small cell lung cancer (NSCLC).

Drugs Make Progress in Breaching the Blood-Brain Barrier

January 4th 2019

Novel agents are showing impressive ability to cross the blood–brain barrier and impair tumor development in several malignancies, raising the prospect of achieving a long-elusive goal of anticancer therapy.

Rare Drivers Emerge as Successful Targets in NSCLC

January 4th 2019

Alexander E. Drilon, MD, discusses the emerging targetable biomarkers in non–small cell lung cancer and the investigational therapies designed to target them.

Forde Forecasts Future Use of Immunotherapy in Early-Stage NSCLC

January 4th 2019

Patrick M. Forde, MBBCh, discusses the future of immunotherapy in early-stage non–small cell lung cancer.

Added Factors Put the Overall Survival Endpoint to the Test

January 3rd 2019

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.

Pembrolizumab Granted 5 Additional Approvals in Japan

January 3rd 2019

The Japan Pharmaceuticals and Medical Devices Agency has approved pembrolizumab for 5 new indications, including melanoma, advanced microsatellite instability-high tumors, and 3 expanded uses in advanced non–small cell lung cancer.

Differentiating Among EGFR Inhibitors in NSCLC

January 3rd 2019

Chul Kim, MD, MPH, discusses the additions of EGFR inhibitors to the lung cancer armamentarium and how to best select therapy for these patients.

Expert Reflects on 2018 Lung Cancer Advancements

January 2nd 2019

Joshua K. Sabari, MD, reflects on the rapidly advancing landscape of lung cancer.

Immunotherapy Advances SCLC Treatment Landscape

December 27th 2018

The new standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer should be atezolizumab and chemotherapy, based on results from the IMpower133 trial.

Randomized Trial Shows Importance of Radiation in NSCLC

December 22nd 2018

Michael D. Mix, MD, disucsses the use and optimization of SBRT in the management of patients with early-stage non–small cell lung cancer and oligometastatic disease.